Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277776 | 0.86 | PRKCI (0.46) | PRKCIGLO1HTR2CEGFRBRPF1 | |
| SCHEMBL3650822 | 0.81 | PRKCI (0.59) | PRKCIHTR2CEGFRBRPF1NTSR1 | |
| SCHEMBL31735936 | 0.81 | GLO1 (0.46) | GLO1HTR2CPLGPLAUMTNR1A | |
| SCHEMBL27593312 | 0.81 | PRKCI (0.47) | PRKCIGLO1EGFRBRPF1NTSR1 | |
| SCHEMBL1612942 | 0.81 | HTR2C (0.55) | GLO1HTR2CNTSR1MTNR1AMTNR1B | |
| SCHEMBL5333977 | 0.81 | HTR2C (0.55) | GLO1HTR2CMTNR1AMTNR1BHTR2A | |
| SCHEMBL21051475 | 0.81 | GLO1 (0.50) | GLO1HTR2CPLGPLAUMTNR1A | |
| SCHEMBL6789563 | 0.80 | PRKCI (0.56) | PRKCIHTR2CEGFRBRPF1NTSR1 | |
| SCHEMBL14117445 | 0.79 | GLO1 (0.46) | GLO1HTR2CPLGPLAUMTNR1A | |
| SCHEMBL5089820 | 0.79 | PRKCI (0.56) | PRKCIHTR2CEGFRBRPF1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768771-A | Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor M5 inhibitors | 范德堡大学 | 2023-03-07 | — | — | CN | claimed |
| EP-2197875-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | claimed |
| WO-2009037222-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| WO-2025245461-A1 | METHODS OF ACTIVATING FOXN1 | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112592334-B | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-115768771-A | Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor M5 inhibitors | 范德堡大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-112592334-A | Pyrimidine derivatives as kinase inhibitors | 艾森生物科学公司 | 2021-04-02 | — | — | CN | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| CN-105916851-A | Pyrimidine derivatives as kinase inhibitors | 艾森生物科学公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| WO-2015006754-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2197875-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009037222-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | PRKCI 1307/4885GLO1 3350/4885HTR2C 1627/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | PRKCI 1307/4885GLO1 3350/4885HTR2C 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.